EI
AGIO icon

EAM Investors’s Agios Pharmaceuticals AGIO Stock Holding History

EAM Investors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-74,273
Closed -$3.3M – 254
2024
Q3 		$3.3M Buy
74,273
+131
+0.2% +$5.95K 0.49% 107
2024
Q2 		$3.2M Buy
+74,142
New +$2.68M 0.52% 104
2015
Q1 		– Sell
-25,905
Closed -$2.9M – 324
2014
Q4 		$2.9M Sell
25,905
-3,602
-12% -$322K 0.41% 74
2014
Q3 		$1.81M Sell
29,507
-11,547
-28% -$498K 0.37% 85
2014
Q2 		$1.88M Buy
41,054
+9,664
+31% +$394K 0.36% 72
2014
Q1 		$1.23M Buy
+31,390
New +$1.05M 0.22% 248

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

EAM Investors's AGIO Position: Q4 2024 in Review

EAM Investors sold out of Agios Pharmaceuticals (AGIO) in Q4 2024, closing a stake of 74,273 shares — an estimated $3.3M sold.

EAM Investors first reported a position in AGIO in Q1 2014 and held it in 6 quarters. The position peaked at $3.3M in Q3 2024. 225 funds tracked by Wall St. Rank hold AGIO as of Q4 2024.

  • EAM Investors reported no remaining Agios Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • EAM Investors sold 74,273 Agios Pharmaceuticals shares in Q4 2024, an estimated $3.3M.
  • EAM Investors first reported a position in Agios Pharmaceuticals in Q1 2014 and held it in 6 quarters.
  • EAM Investors's Agios Pharmaceuticals position peaked at $3.3M in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.